Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France. 

CEO
Belén Garijo López
CEOBelén Garijo López
Employees
76,493
Employees76,493
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1973
Founded1973
Employees
76,493
Employees76,493

SNY Key Statistics

Market cap
112.75B
Market cap112.75B
Price-Earnings ratio
24.34
Price-Earnings ratio24.34
Dividend yield
3.72%
Dividend yield3.72%
Average volume
5.14M
Average volume5.14M
High today
$47.88
High today$47.88
Low today
$46.72
Low today$46.72
Open price
$47.48
Open price$47.48
Volume
7.11M
Volume7.11M
52 Week high
$52.68
52 Week high$52.68
52 Week low
$39.07
52 Week low$39.07

SNY News

Investor's Business Daily 1d
Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development

Technology Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development Licensing Shares of Nurix Therapeutics (NRIX) crashed Wednesday after S...

Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
Zacks 1d
RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway

Recursion Pharmaceuticals, Inc. (RXRX Quick QuoteRXRX - Free Report) emphasized clinical progress, disciplined spending and an extended cash runway on its...

RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway
Investing.com 2d
Sanofi discontinues Nurix drug trial, terminates program - Investing.com

...

Sanofi discontinues Nurix drug trial, terminates program - Investing.com

Analyst ratings

50%

of 10 ratings
Buy
50%
Hold
50%
Sell
0%

More SNY News

Benzinga 6d
Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It

Sanofi SA (NASDAQ:SNY) on Friday reported third-quarter sales of $16.623 billion (14.444 billion euros), beating the consensus of $15.23 billion. Sales increase...

Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It
The Wall Street Journal 6d
Health Care Roundup: Market Talk

george frey / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
Seeking Alpha 7d
Sanofi lifts profit outlook on strong Dupixent sales

Sanofi (SNY) raised its full-year 2026 guidance after reporting stronger-than-expected third-quarter results, supported by robust growth in its pharmaceutical l...

Sanofi lifts profit outlook on strong Dupixent sales
The Wall Street Journal 7d
Sanofi CEO Sets Sights on Deals to Drive Turnaround

Sanofi attributed the guidance upgrade to its strong commercial and financial momentum. Sylvain Thomas / Agence France-Presse / Getty Images Sanofi’s SAN 0.85...

Sanofi CEO Sets Sights on Deals to Drive Turnaround

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.